Register
Upcoming Conference
Chicago, June 8, 2023



  • Conferences
    • 2023 Illinois State of Reform Health Policy Conference
    • 2023 Maryland State of Reform Health Policy Conference
    • 2023 Arizona State of Reform Health Policy Conference
    • 2023 Tennessee State of Reform Health Policy Conference
    • 2023 Oregon State of Reform Health Policy Conference
    • All Conferences
    • 2023 Conference Schedule
  • Conversations
    • Past Conversations
  • News
    • alaska
    • arizona
    • california
    • colorado
    • florida
    • hawaii
    • illinois
    • maryland
    • michigan
    • oregon
    • texas
    • utah
    • washington
    • Federal
  • Intelligence
    • 5 Things We’re Watching
    • 5 Slides We’re Discussing
    • What They’re Watching
    • Interviews
    • Podcasts
  • Videos
  • About
  • ABOUT
  • SUBSCRIBE
  • Conferences
    • 2023 Illinois State of Reform Health Policy Conference
    • 2023 Maryland State of Reform Health Policy Conference
    • 2023 Arizona State of Reform Health Policy Conference
    • 2023 Tennessee State of Reform Health Policy Conference
    • 2023 Oregon State of Reform Health Policy Conference
    • All Conferences
    • 2023 Conference Schedule
  • Conversations
    • Past Conversations
  • News
    • alaska
    • arizona
    • california
    • colorado
    • florida
    • hawaii
    • illinois
    • maryland
    • michigan
    • oregon
    • texas
    • utah
    • washington
    • Federal
  • Intelligence
    • 5 Things We’re Watching
    • 5 Slides We’re Discussing
    • What They’re Watching
    • Interviews
    • Podcasts
  • Videos
  • About
  • SUBSCRIBE

5 Slides: Gene therapy and the promise for rare disease

January 18, 2022 | Virtual

Overview
Register

Overview

Gene therapy has yielded promising results for treating various life-threatening rare diseases like muscular dystrophy and cystic fibrosis. This is groundbreaking for individuals living with rare disease, whose limited treatment options often entail ongoing, high-cost medical visits. However, these new treatments are entering the market at considerably high prices and posing affordability challenges for patients. We’ve convened a group of rare disease experts to talk through the potential that gene therapy has to treat rare diseases, and how to navigate their financial barriers.

Date: Tuesday, Jan. 18th, 2022

Time: 1:00 – 2:00pm MST

Panelists:

    • Rafael Fonseca: Chief Innovation Officer, Mayo Clinic
    • Jennifer Hodge: US DMD Gene Therapy Lead,, Pfizer
    • Danny Seiden: President & Chief Executive Officer, Arizona Chamber of Commerce and Industry
    • Sharon Hesterlee, MD: Chief Research Officer, Muscular Dystrophy Association

 

Rafael Fonseca is the Chief Innovation Officer at Mayo Clinic. He is also a practicing hematologist specializing in care and research of myeloma and related conditions. Within Mayo Clinic, he served as director of the Comprehensive Cancer Center, associate director for the Center of Individualized Medicine in Arizona, and the chair of the Department of Internal Medicine in Arizona. He is also a Mayo Clinic Distinguished Investigator, the highest academic distinction of investigators.

Jennifer Hodge is the US DMD Gene Therapy Lead at Pfizer. Over the past 9 years, she has contributed in roles of increasing responsibility across Early Pipeline/Gene Therapy, Sickle Cell Disease, Hemophilia and I&I where she played an important role in the US & EU launches of XELJANZ for Rheumatoid arthritis. She received her PhD in Immunology and completed two Post-Doctoral Fellowships at Harvard Medical School & the Yale University School of Medicine.

Danny Seiden is the President and Chief Executive Officer of the Arizona Chamber of Commerce and Industry. Danny brings over 16 years of experience in global public affairs and government relations. Prior to joining the Arizona Chamber of Commerce & Industry, Danny was General Counsel to the Valor Global leadership team. He worked at Intel, was a shareholder at Greenberg Traurig where he chaired the Phoenix office government law and policy practice.

Sharon Hesterlee is the Chief Research Officer of the Muscular Dystrophy Association. She has over 20 years of experience in neuromuscular research in both the nonprofit and industry space. Dr. Hesterlee has also served as project lead for rare disease gene therapy programs at Pfizer, Inc; as Chief Executive Officer of Lion Therapeutics & Executive Vice President of the Neuromuscular Division of Askbio Inc.

Register

This event is free to attend but registration is required. If you have trouble registering, please send us an email and we will get you taken care of!

Top 5 Stories in the Southwest Edition

  • Colorado CapitolColorado lawmakers adjourn ‘progressive’ session on healthcare
  • Colorado to make numerous reforms to its Behavioral Health Administration to address operational delays
  • Texas bill proposing Medicaid regulations to ensure direct care for long-term care residents scheduled for hearing
  • Colorado PDAB approves list of eligible prescription drugs for affordability reviews
  • Utah Medicaid Director outlines state strategy on redeterminations
  • Conferences
    • 2023 Illinois State of Reform Health Policy Conference
    • 2023 Maryland State of Reform Health Policy Conference
    • 2023 Arizona State of Reform Health Policy Conference
    • 2023 Tennessee State of Reform Health Policy Conference
    • 2023 Oregon State of Reform Health Policy Conference
    • All Conferences
    • 2023 Conference Schedule
  • Conversations
    • Past Conversations
  • News
    • alaska
    • arizona
    • california
    • colorado
    • florida
    • hawaii
    • illinois
    • maryland
    • michigan
    • oregon
    • texas
    • utah
    • washington
    • Federal
  • Intelligence
    • 5 Things We’re Watching
    • 5 Slides We’re Discussing
    • What They’re Watching
    • Interviews
    • Podcasts
  • Videos
  • About
Tweets by StateofReform
  • 
  • 
  • 
  • 
© 2023 State of Reform. All rights reserved.
Privacy Policy
 

Loading Comments...